Announcements Trials
Browse Landscape

Phase

Phase 2 43Phase 1/2 16Phase 3 11Phase 1 10Phase 4 4

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 9Zoledronic Acid 8ixazomib 4daratumumab 4Melphalan 4tocilizumab 3Thalidomide 3Cyclophosphamide 3pomalidomide 2carfilzomib 2Prednisone 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1Vaccination 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Multiple Myeloma × ixazomib × Clear all
NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Takeda

Phase 4 Terminated
141 enrolled
Plasma cell

Multiple Myeloma

NCT05722405 2026-01-05

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Recruiting
100 enrolled
Plasma cell

Multiple Myeloma

NCT04217967 2024-08-01

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Peking Union Medical College Hospital

Phase 4 Completed
211 enrolled
Plasma cell

Multiple Myeloma

NCT05183139 2022-05-03

US MM-7

Takeda

Phase 4 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡